91 related articles for article (PubMed ID: 16304247)
21. Comparative randomized trial of azithromycin versus erythromycin and amoxicillin for treatment of community-acquired pneumonia in children.
Kogan R; Martínez MA; Rubilar L; Payá E; Quevedo I; Puppo H; Girardi G; Castro-Rodriguez JA
Pediatr Pulmonol; 2003 Feb; 35(2):91-8. PubMed ID: 12526069
[TBL] [Abstract][Full Text] [Related]
22. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
Griffin AT; Peyrani P; Wiemken T; Arnold F
Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
Wasserfallen JB; Erard V; Cometta A; Calandra T; Lamy O
Eur Respir J; 2004 Oct; 24(4):644-8. PubMed ID: 15459145
[TBL] [Abstract][Full Text] [Related]
24. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
25. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
[TBL] [Abstract][Full Text] [Related]
26. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
Rakov AL; Grinevich VB; Kriukov AE; Bogdanov IV; Rysev AV; Zakharchenko MM; Dobrenko VA; Gubonina IV
Voen Med Zh; 2006 Apr; 327(4):15-22. PubMed ID: 16784101
[No Abstract] [Full Text] [Related]
27. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Marrie TJ
Chemotherapy; 2004; 50 Suppl 1():11-5. PubMed ID: 15319549
[TBL] [Abstract][Full Text] [Related]
28. " 'Tis a gift to be simple...".
Wunderink RG
Chest; 2003 Sep; 124(3):777-8. PubMed ID: 12969994
[No Abstract] [Full Text] [Related]
29. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
Brixner DI
Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
[No Abstract] [Full Text] [Related]
30. Monotherapy in severe community-acquired pneumonia: is it worthy?
Torres A
Chest; 2005 Jul; 128(1):10-3. PubMed ID: 16002907
[No Abstract] [Full Text] [Related]
31. Community-acquired pneumonia: need for a cost-effective approach to treatment.
Prabhudesai PP; Kuruvilla T; Tadvi S
Chest; 1997 Sep; 112(3):861-2. PubMed ID: 9315836
[No Abstract] [Full Text] [Related]
32. Clinical effects and bronchoalveolar transfer of levofloxacin in patients with community-acquired pneumonia.
Lin Y; Su W; Xu Z; Bai Y
Chin Med J (Engl); 2001 Feb; 114(2):212-3. PubMed ID: 11780213
[No Abstract] [Full Text] [Related]
33. Oral levofloxacin in the treatment of community-acquired pneumonia.
Nicodemo AC; Lima Nicodemo E; Idrahim KY
Braz J Infect Dis; 2000 Apr; 4(2):61-6. PubMed ID: 10795070
[TBL] [Abstract][Full Text] [Related]
34. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
Starodubtseva OI; Vakhrushev IaM
Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
[TBL] [Abstract][Full Text] [Related]
35. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
Goldstein RC; Husk G; Jodlowski T; Mildvan D; Perlman DC; Ruhe JJ
Am J Infect Control; 2014 May; 42(5):539-41. PubMed ID: 24773792
[TBL] [Abstract][Full Text] [Related]
36. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.
Malcolm C; Marrie TJ
Arch Intern Med; 2003 Apr; 163(7):797-802. PubMed ID: 12695270
[TBL] [Abstract][Full Text] [Related]
37. Role of gemifloxacin in community-acquired pneumonia.
Tillotson GS
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107
[TBL] [Abstract][Full Text] [Related]
38. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin.
Sollet JP
Int J Antimicrob Agents; 2006 Sep; 28 Suppl 2():S113-4. PubMed ID: 16904296
[TBL] [Abstract][Full Text] [Related]
39. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin/sulbactam in hospitalized patients with community-acquired pneumonia.
Todisco T; Dal Farra F; Ciliberti G; Pirina P; Guelfi R; Serra G; Paris R; Mancuso I; Cepparulo M
J Chemother; 2008 Apr; 20(2):225-32. PubMed ID: 18467250
[TBL] [Abstract][Full Text] [Related]
40. Doxycycline for nursing home acquired pneumonia (NHAP).
Cunha BA
Scand J Infect Dis; 2009; 41(1):77-8, author reply 76. PubMed ID: 18821134
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
